Leukemias

Edited by experts from one of the world's largest leukemia
centers, this book provides information on the biology of the
variety of leukemic disorders, up-to-date diagnostic testing and
many new developments in therapy. Chapters covering new treatments
present an outlook for the future and explain the rationale for
ongoing clinical trials.

Topics include:

• Targeted therapy, e.g. tyrosine kinase inhibitors (Flt3, Aurora
  kinase inhibitors, kit inhibitors, BCR-ABL inhibitors)

• Ras inhibitors

• Epigenetic therapy (hypomethylaters and histone deacetylase
  inhibitors)

• Lenalidomide analogs

• New chemotherapy drugs, e.g. clofarabine, cloretazine,
  sapacitabine, forodesine

• Combinations of chemotherapy with kinase inhibitors (e.g. ALL
  induction protocols in combination with dasatinib or imatinib)

• New monoclonal antibodies (lumiliximab, humaxCD20,
  anti-CD40)

• Thrombopoietic agents

Leukemias: Principles and Practice of Therapy

• Includes practical information to guide you in challenging
  situations, such as treatment of elderly patients, pregnancy,
  relapsed and refractory disease

• Incorporates chapters on supportive care and pharmacologic
  information about the most frequently used drugs in this area

Autorentext

Dr. Stefan Faderl specializes in acute and chronic leukemias. His main areas of interest include acute lymphoblastic leukemias (ALL), acute myeloid leukemias (AML), chronic lymphocytic leukemia (CLL) and its variants, as well as chronic myeloid leukemias (CML). Dr. Hagop M. Kantarjian is Professor of Medicine and Chairman of the Department of Leukemia at MD Anderson Cancer Center in Houston, Texas. He specializes in leukemia and is interested in creating new treatment approaches for these diseases. He has authored and contributed to over 560 medical publications, articles, and abstracts.

Zusammenfassung
Edited by experts from one of the world's largest leukemia centers, this book provides information on the biology of the variety of leukemic disorders, up-to-date diagnostic testing and many new developments in therapy. Chapters covering new treatments present an outlook for the future and explain the rationale for ongoing clinical trials. Topics include:

• Targeted therapy, e.g. tyrosine kinase inhibitors (Flt3, Aurora kinase inhibitors, kit inhibitors, BCR-ABL inhibitors)
• Ras inhibitors
• Epigenetic therapy (hypomethylaters and histone deacetylase inhibitors)
• Lenalidomide analogs
• New chemotherapy drugs, e.g. clofarabine, cloretazine, sapacitabine, forodesine
• Combinations of chemotherapy with kinase inhibitors (e.g. ALL induction protocols in combination with dasatinib or imatinib)
• New monoclonal antibodies (lumiliximab, humaxCD20, anti-CD40)

• Thrombopoietic agents
  Leukemias: Principles and Practice of Therapy

• Includes practical information to guide you in challenging situations, such as treatment of elderly patients, pregnancy, relapsed and refractory disease
• Incorporates chapters on supportive care and pharmacologic information about the most frequently used drugs in this area

Inhalt
Contributors. Preface.

Part 1: Background and Diagnostic.

1. Stem Cell Biology in Normal and Malignant Hematopoiesis (Amer Zeidan and Meir Wetzler).

2. Epidemiology and Etiology of Leukemias (Andrew Fletcher, Annika Whittle and David Bowen).

3. Traditional Diagnostic Approaches (Hartmut Koeppen, Carlos E. Bueso-Ramos and Sergej N. Konoplev).

4. Diagnosis of Leukemias - New Diagnostic Modalities and Implications for Classification (Maher Albitar).

5. Non-cytogenetic Markers and Their Impact on Prognosis (Eric Schafer and Donald Small).

Part 2: Myelodysplastic syndromes (MDS).

6. Myelodysplastic Syndromes: Pathophysiology (Steven D. Gore and Erica Warlick).

7. Myelodysplastic Syndromes - The Role of Cytogenetic and Molecular Abnormalities for Classification and Risk Assignment (Ulrich Germing).

8. Myelodysplastic Syndromes (William Stevenson and Guillermo Garcia-Manero).

Part 3: Acute Myeloid Leukemia (AML).

9. Presentation and Diagnosis: Novel Molecular Markers and their Role in the Prognosis and Therapy of Acute Myeloid Leukemia (Wolfgang Kern, Torsten Haferlach, Susanne Schnittger, Claudia Haferlach, and Ulrike Bacher).

10. Induction Therapy of Acute Myeloid Leukemia (Martha Wadleigh and Daniel J. DeAngelo).

11. Salvage Therapy for Acute Myeloid Leukemia: Current Strategies and Emerging Therapies (Keith W. Pratz and Judith E. Karp).

12. Hematopoietic Stem Cell Transplantation for Acute Myelogenous Leukemia (Gheath Alatrash and Marcos de Lima).

Part 4: Acute Promyelocytic Leukemia (APL).

13. The Pathophysiology of Acute Promyelocytic Leukemia (Francesco Lo-Coco and Syed Khizer Hasan).

14. Acute Promyelocytic Leukemia (APL): Manifestations and Therapy (Sylvain Thépot, Lionel Ades, Pierre Fenaux).

Part 5: Acute Lymphoblastic Leukemia (ALL).

15. Acute Lymphoblastic Leukemia: Presentation, Diagnosis and Classification (Sandeep Gurbuxani and John Anastasi).

16. Induction Therapy in Adult Acute Lymphoblastic Leukemia (Xavier Thomas).

17. Salvage Therapy of Adult Acute Lymphoblastic Leukemia (Nicola Gökbuget and Dieter Hoelzer).

18. Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Current Treatment Status and Perspectives (Olga Sala-Torra and Jerald P. Radich).

19. Acute Lymphoblastic Leukemia in Adolescents and Young Adults (Michael E. Rytting).

20. The Role of Hematopoietic Stem Cell Transplantation in Adults with Acute Lymphoblastic Leukemia (Partow Kebriaei).

Part 6: Chronic Myeloid Leukemia (CML).

21. Pathophysiology of Chronic Myeloid Leukemia (Agnes S. M. Yong and Junia V. Melo).

22. Therapy of Newly Diagnosed and Chronic Phase Chronic Myelogenous Leukemia (Andreas Hochhaus).

23. Therapy of Advanced Stage and Resistant Chronic Myeloid Leukemia (Devendra K. Hiwase and Timothy P. Hughes).

Part 7: Chronic Lymphocytic Leukemia.

24. Chronic Lymphocytic Leukemia: Pathophysiology, Diagnosis and Manifestations, and Prognostic Markers (Thorsten Zenz, Hartmut Döhner, Stephan Stilgenbauer).

25. Therapy of Chronic Lymphocytic Leukemia Frontline and Salvage (Valentin Goede, Barbara Eichhorst, and Michael Hallek).

26. The Role of Stem Cell Transplantation in Chronic Lymphocytic Leukemia (Simon Hallam and John G. Gribben).

27. Special Situations: Management of Elderly Patients and CLL Transformation (Wei-Gang Tong and Alessandra Ferrajoli).

Part 8: Other Leukemic Disorders.

28. Hairy Cell Leukemia (Farhad Ravandi).

29. Therapeutic Approaches to the Mature T-cell Lymphoproliferative Leukaemias (Nnenna Osuji and Claire Dearden).

    30. Philadelphia Chromosome Neg...